Sangamo BioSciences Enters Research Collaboration with Pfizer to Enhance Protein Production

Strategic Insights

Jan 30, 2005 — 1 min read

Sangamo BioSciences, Inc. (NASDAQ:SGMO) has teamed up with Pfizer Inc to develop novel technologies for protein production. Under the agreement, Pfizer will fund research at Sangamo's facilities, and the company will utilize its proprietary zinc finger DNA binding protein (ZFP) technology to create enhanced cell lines for protein production. This collaboration aims to leverage Sangamo's expertise in DNA regulation and modification to improve the efficiency and robustness of protein production in mammalian cells.

Key Takeaways:

Sangamo BioSciences has entered into a research collaboration with Pfizer Inc to develop novel technologies for protein production.
Pfizer will fund research at Sangamo's facilities, utilizing the company's zinc finger DNA binding protein (ZFP) technology.
Sangamo will generate novel cell lines and vector systems for enhanced protein production, as well as novel technology for rapid and robust creation of new production cell lines.
Edward Lanphier, Sangamo's president and chief executive officer, expressed excitement about collaborating with Pfizer, the world's leading research-based pharmaceutical company.
Zinc finger DNA-binding proteins (ZFPs) are engineered to facilitate the efficient generation of production cell lines with altered traits.
Sangamo's ZFP technology is used to regulate genes expressing protein pharmaceuticals, providing precise targeting to specific genes of interest.
This collaboration is a significant step forward in Sangamo's research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.

Statistics:

No specific statistics were mentioned in the article.
Under the agreement, Pfizer will fund research at Sangamo's facilities.
Sangamo will utilize its proprietary ZFP technology to create enhanced cell lines for protein production.
The financial terms of the agreement were not disclosed.

Sources:

NewsRx.com & NewsRx.net - Health & Medicine Week

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients